Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals aimed at expanding treatment options for cancer patients. The company utilizes a proprietary miniprotein radioconjugate platform to deliver alpha-emitting radioisotopes to tumors, enhancing therapeutic efficacy while minimizing systemic exposure. By broadening the scope of tumor targets, Aktis Oncology seeks to maximize clinical utility across multiple indications and expand the commercial uptake of radiopharmaceuticals beyond traditional settings.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $1.5M | Not provided | Not provided |
| Adjusted Net Loss | -$44.0M | -$28.6M | Not provided |
| Margin % | -2933.3% | - | - |
The company operates in the oncology market and competes with established players like Novartis and Bayer in the radiopharmaceuticals sector.
Aktis Oncology plans to use the proceeds from the IPO to advance its clinical programs and expand its operational capabilities.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.